We round up this week’s big health tech investment news
Do you have an investment story to share with us?
Email [email protected]
Level Zero Health raises £5.5 million in pre-seed funding
UK-based hormone-tracking start-up Level Zero Health has successfully raised $6.9 million (£5.5 million) in pre-seed funding.
The figure is the largest raise to date by female founders in Europe.
The funds will help further develop the company’s remote and continuous hormone-monitoring device – a wearable arm patch that uses novel DNA-based sensors.
Chief Executive Ula Rustamova hsaid: “Our innovative remote monitoring technology marks an enormous leap in hormone testing.
“This funding will enable us to bring this revolutionary solution to the market, making hormone tracking more accessible and insightful than ever before.”
GenAI platform Abridge announces $250m Series D
Abridge, the generative AI platform for clinical conversations, has raised a $250 million Series D investment.
The investment will fuel additional development of AI capabilities and commercial growth to support broader applications.
Abridge has also introduced a new Contextual Reasoning Engine—an AI architecture that produces more clinically useful and billable notes at the point of care.
Matt Kull is Executive Vice President, Chief Information and Digital Officer, Inova.
He said: “We are excited about the potential of Abridge’s technology to enhance Inova’s clinical documentation across our care sites.
“The quality of specialty-specific notes and Abridge’s responsiveness to clinician feedback with rigorously tested enhancements stood out to us.
“Learning more about the innovation behind the scenes—ensuring notes are both clinically useful and billing compliant—along with the demonstrated ROI at other institutions has been compelling as we explore this solution.”
Perceive Pharma raises $15m Series A financing to advance to ophthalmic neuroprotection
Perceive Pharma, a pharmaceutical company developing novel small molecule therapeutics in ophthalmology, has announced the closing of a $15m Series A funding round.
Perceive Pharma, Inc. was spun out from Perceive Biotherapeutics, Inc. to accelerate development of novel neuroprotective therapeutics in glaucoma and other indications.
Series A proceeds will advance the development of first-in-class therapies to prevent vision loss in glaucoma, and additional undisclosed disease areas.
CEO K. Angela Macfarlane said: “All approved drugs for glaucoma target the lowering of intraocular pressure, but about half of glaucoma patients have normal pressures and continue to lose vision.
“The deep science underlying the identification of Perceive’s targets differentiates its programmes and provides promise for new, transformative treatments for sight-saving therapies for the more than 1.5 million Americans and others worldwide with glaucoma whose disease is continuing to progress, despite access to current treatments.”
Posterity Health secures $13m Series A to expand male reproductive care
Male reproductive and hormonal healty company Posterity Health has secured $13 million in Series A funding to expand access to comprehensive care for men nationwide.
Posterity Health provides solutions to address fertility challenges, optimise hormone levels, and manage long-term health risks, combining cutting-edge technology with expert clinical care.
Through its telehealth services, at-home diagnostics, and in-person care, the company aims to be a partner for men at every stage — from family building and fertility optimisation to hormone management, vasectomies, low-testosterone treatments, and more.
Pam Pure is the CEO and Co-Founder of Posterity Health.
Pure said: “I’ve committed my career to male reproductive health because it remains one of the most underserved and poorly understood areas within healthcare.
“This funding gives us the opportunity to serve more men and their families, and it also demonstrates that the tide is turning and that men are starting to take a more active role in their own health.”
Avandra launches with $17.75m in funding to advance use of real-word medical data
Avandra, the federated network for medical imaging and clinical data, has raised $17.75 million to accelerate the use of imaging-centric data for research and patient care.
The capital will be used to further develop Avandra’s platform, expand its data network through partnerships with major health systems and providers, and scale its commercial initiatives with biopharma and medical researchers.
Murray Brozinsky, who is Aegis Partner and former CEO of Conversa Health, will serve as Executive Chair of the Board.
Brozinsky said: “We have very high conviction about the ability of real-world data to dramatically improve treatments, care plans, and equitable access for patients.
“And we believe health systems hold the keys to this future.
“Avandra is taking a novel approach to partnering with health systems to unlock this valuable data.”
